Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

Autor: Mark E. Bangs, David Kudrow, Shufang Wang, Tina M. Oakes, Gisela M. Terwindt, Delphine Magis, Laura Yunes-Medina, Virginia L. Stauffer

Publikováno v: BMC Neurology, Vol 20, Iss 1, Pp 1-18 (2020)

Abstract Background Galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days in phase 2 and 3 trials. In these analyses, we aim

Externí odkaz: https://doaj.org/article/af4da3097c394172a6b4fad083f09ebd

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment

Autor: Phebe Kemmer, Miguel J. A. Láinez, Mark E. Bangs, Jean Schoenen, Tina M. Oakes, Jennifer N. Bardos, Chad Stroud, James M. Martinez, Richard Wenzel, Dulanji K. Kuruppu

Publikováno v: Headache: The Journal of Head and Face Pain. 62:65-77

Objective The objective of the study was to assess the tolerability and safety of galcanezumab in patients with chronic cluster headache (CH) with up to 15 months of treatment. Background Chronic CH is a highly debilitating disease with a substantial

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3c99d053dd936ae8c5d80e8a42312db0
https://doi.org/10.1111/head.14234

Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment

Autor: Rigmor Jensen, Sheena K. Aurora, Jyun Yan Yang, James M. Martinez, Tina M. Oakes, David W. Dodick, Christian Lucas, Jennifer N. Bardos, Peter J. Goadsby, Chunmei Zhou, Robert R. Conley

Publikováno v: Cephalalgia
Dodick, D W, Goadsby, P J, Lucas, C, Jensen, R, Bardos, J N, Martinez, J M, Zhou, C, Aurora, S K, Yang, J Y, Conley, R R & Oakes, T 2020, ' Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache : Results from 3-month double-blind treatment ', Cephalalgia, vol. 40, no. 9, pp. 935-948 . https://doi.org/10.1177/0333102420905321

Objective To report efficacy and safety of galcanezumab in adults with chronic cluster headache. Background Galcanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide and inhibits its biological activity. Methods Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83f0b9d69267fd20b510a3ff6fa6706
https://doi.org/10.1177/0333102420905321

Trial of Galcanezumab in Prevention of Episodic Cluster Headache

Autor: Tina M. Oakes, Peter J. Goadsby, Chunmei Zhou, Massimo Leone, Brian A. Millen, David W. Dodick, James M. Martinez, Andrew H. Ahn, Robert R. Conley, Jennifer N. Bardos, Sherie A. Dowsett, Jyun Yan Yang, Sheena K. Aurora

Publikováno v: New England Journal of Medicine. 381:132-141

Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc3f1dcf679063529ab4b29914d82fa
https://doi.org/10.1056/nejmoa1813440

Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis

Autor: Virginia L, Stauffer, Tina M, Oakes, Mallikarjuna, Rettiganti, Kathleen A, Day, Angelo, Camporeale

Publikováno v: Journal of neurology. 268(5)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::090424f8a563e559da449d42d2359613
https://pubmed.ncbi.nlm.nih.gov/33590341